Nurix Therapeutics disclosed that Sanofi had discontinued development of SAR448272, an oral investigational therapy for autoimmune and inflammatory diseases, following termination of its early-stage clinical trial. Nurix will no longer receive potential development, regulatory, or commercial milestones or royalties from that program, although other partnered assets remain eligible for payments. Its shares fell approximately 38% in extended trading, and Nurix reported about $1.1 billion in cash, cash equivalents, and marketable securities as of August 31, with management projecting funding into the second half of 2029. The publicly available announcement does not establish Sanofi's specific reason for termination.
Reuters
Source: Reuters, November 3
Why it matters strategically
This is a direct illustration of the asymmetry inherent in pharmaceutical licensing.
A biotechnology company may obtain funding and scientific validation through a major pharmaceutical partnership, but its future economic returns remain dependent on the partner's clinical and portfolio decisions.
The termination removes a potential revenue stream without necessarily invalidating Nurix's broader targeted protein degradation platform.
